April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Prospective Comparison of the Effects of Intravitreal Injections of Bevacizumab and Triamcinolone Acetonide for Macular Edema Due to Branch Retinal Vein Occlusion
Author Affiliations & Notes
  • T. Higashiyama
    Opthalmology, Shiga University of Medical Science, Otsu, Japan
  • O. Sawada
    Opthalmology, Shiga University of Medical Science, Otsu, Japan
  • M. Kakinoki
    Opthalmology, Shiga University of Medical Science, Otsu, Japan
  • T. Sawada
    Opthalmology, Shiga University of Medical Science, Otsu, Japan
  • H. Kawamura
    Opthalmology, Shiga University of Medical Science, Otsu, Japan
  • M. Ohji
    Opthalmology, Shiga University of Medical Science, Otsu, Japan
  • Footnotes
    Commercial Relationships  T. Higashiyama, None; O. Sawada, None; M. Kakinoki, None; T. Sawada, None; H. Kawamura, None; M. Ohji, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5394. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Higashiyama, O. Sawada, M. Kakinoki, T. Sawada, H. Kawamura, M. Ohji; Prospective Comparison of the Effects of Intravitreal Injections of Bevacizumab and Triamcinolone Acetonide for Macular Edema Due to Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5394.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the effect of an intravitreal injection of bevacizumab with that of triamcinolone acetonide (TA) for macular edema due to branch retinal vein occlusion (BRVO).

Methods: : Forty eyes of 40 patients with macular edema due to BRVO were assigned randomly to either an intravitreal 1.25-mg bevacizumab injection or intravitreal 4-mg TA injection. All patients were followed for 3 month without additional treatment. The changes in the best-corrected visual acuity (BCVA) (logMAR) and the central retinal thickness (CRT) were measured at 1 week and 1 and 3 months after the injection.

Results: : Nineteen patients in the bevacizumab group and 18 patients in the TA group completed the 3-month follow-up. Before the injection, the BCVA and CFT were, respectively, 0.59 ± 0.16 and 613 ± 191 µm in the bevacizumab group, and 0.62 ± 0.26 and 638 ± 193 µm in the TA group, differences that were not significantly different. The BCVA in the bevacizumab group improved at all visits compared to baseline (p<0.05). The BCVA in the TA group did not improve at any visit compared to baseline. The difference between the two groups did not reach significance. The CRT in both groups decreased significantly (p<0.05) at all time points. The mean changes in the CRT between the bevacizumab group and the TA group were not significantly different at 1 week and 1 month after the injection; however, the change in the TA group was significantly (p<0.05) better compared to the bevacizumab group 3 months after the injection.

Conclusions: : Intravitreal TA is effective and seems to maintain the treatment effect longer compared to intravitreal bevacizumab for macular edema due to BRVO.

Clinical Trial: : www.umin.ac.jp/ctr/index/htm UMIN000001546

Keywords: vascular occlusion/vascular occlusive disease • visual acuity • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×